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Abstract
Background:  Niemann-Pick disease type A and B is caused by a deficiency of acid
sphingomyelinase due to mutations in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. In
Niemann-Pick patients, SMPD1 gene defects are reported to be associated with a severe reduction
in plasma high-density lipoprotein (HDL) cholesterol.
Methods: Two common coding polymorphisms in the SMPD1 gene, the G1522A (G508R) and a
hexanucleotide repeat sequence within the signal peptide region, were investigated in 118
unrelated subjects of French Canadian descent with low plasma levels of HDL-cholesterol (< 5th
percentile for age and gender-matched subjects). Control subjects (n = 230) had an HDL-
cholesterol level > the 25th percentile.
Results: For G1522A the frequency of the G and A alleles were 75.2% and 24.8% respectively in
controls, compared to 78.6% and 21.4% in subjects with low HDL-cholesterol (p = 0.317). The
frequency of 6 and 7 hexanucleotide repeats was 46.2% and 46.6% respectively in controls,
compared to 45.6% and 49.1% in subjects with low HDL-cholesterol (p = 0.619). Ten different
haplotypes were observed in cases and controls. Overall haplotype frequencies in cases and
controls were not significantly different.
Conclusion: These results suggest that the two common coding variants at the SMPD1 gene locus
are not associated with low HDL-cholesterol levels in the French Canadian population.
Background
A low plasma level of high-density lipoprotein (HDL)
cholesterol is defined as a cardiovascular risk factor and is
part of the assessment of global cardiovascular risk strati-
fication [1]. Therapeutic goals set for the prevention of
cardiovascular disease include targets for low density lipo-
protein (LDL) cholesterol, non-HDL-cholesterol [2], and
the total cholesterol to HDL-cholesterol ratio [3]. How-
ever, a goal for an absolute HDL-cholesterol value is still a
matter of controversy as the current therapeutic
approaches are limited in their ability to raise HDL-
cholesterol [4]. In the majority of cases, a low HDL-
cholesterol is secondary to increased hepatic secretion of
apolipoprotein B-containing lipoproteins and triglycer-
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ides [5]. Some cases of low HDL-cholesterol are due to
genetic defects in HDL-associated protein apolipoprotein
A-I, modifying enzymes (hepatic lipase, lipoprotein
lipase, cholesteryl ester transfer protein, lecithin:choles-
terol acyl transferase) and the ATP binding cassette A1
transporter [6].
Niemann-Pick disease type A and B is caused by a defi-
ciency of the enzyme acid sphingomyelinase coded by
SMPD1 gene. SMPD1 gene defects are reported to be asso-
ciated with a severe reduction in plasma HDL-cholesterol
[7]. In the search for genes causing disorders of HDL-cho-
lesterol, we examined extended (3 or more generations)
kindred of French Canadian descent to identify Mende-
lian traits. Using this approach, we have previously
reported that compound heterozygosity in the SMPD1
gene is associated with decreased activity of acid sphingo-
myelinase and low HDL-cholesterol [8]. Furthermore, a
decreased activity of lysosomal and secreted acid sphingo-
myelinase is believed to cause low HDL-cholesterol in
part by decreased activation of lecithin:cholesterol acyl-
transferase (LCAT) and impaired formation of cholesteryl
ester-enriched HDL particles [9]. The SMPD1  gene is
located on chromosome 11p15.1-p15.4, is comprised of
6 exons, and encodes a cDNA of 2.5 kb. The acid sphingo-
myelinase protein [10] consists of 631 amino acids and
exists in at least three protein isoforms. The protein also
contains a signal peptide, a saposin domain that is com-
mon in lysosome-targeted proteins, and a large metallo-
phosphoesterase domain. Although rare mutations in the
SMPD1 gene can impair the function of acid sphingomy-
elinase and result in Niemann-Pick disease type A or B, as
well as in low HDL-cholesterol, it is not known whether
common amino acid change variants in SMPD1 can mod-
ulate HDL-cholesterol levels within a population. The
objective of this study was to investigate, in a population
selected for HDL-cholesterol levels, associations between
known common amino acid variants of the SMPD1 gene
and low plasma levels of HDL-cholesterol in subjects of
French Canadian descent. We focused on frequent (> 5%
in the general population) polymorphisms that affect the
coding sequence of SMPD1.
Methods
Subject characteristics
A total of 348 unrelated subjects of French Canadian ori-
gin (118 with low HDL-cholesterol levels and 230 control
subjects) were examined at the McGill University Health
Centre. Low HDL-cholesterol levels were defined as those
less than the 5th percentile (age and gender-matched),
based on the Lipid Research Clinics Population Studies
Data Book [11]. Subjects with low HDL-cholesterol had
no known cause of HDL deficiency (severe hypertriglycer-
idemia defined as plasma triglycerides > 10 mmol/L, cel-
lular phospholipid or cholesterol efflux defect or
previously known mutations in genes associated with
HDL deficiency). The control group was of same origin
and chosen based on HDL-cholesterol levels > 25th per-
centile, matched for age and gender. Demographic and
clinical information, medications, blood pressure, and
lipoprotein profiles were determined on all participating
subjects. Hypertension was defined as a blood pressure ≥
130/85 mmHg. Coronary artery disease (CAD) was
present when angiographically documented or patient
had a past history of acute myocardial infarction. Consent
was obtained for the plasma sampling and DNA isolation.
The research protocol was reviewed and approved by the
Research Ethics Board of the McGill University Health
Centre (REB No. BMA 05-006).
Measurement of plasma lipids and lipoprotein
The lipid lowering agents were withdrawn in all study sub-
jects for at least four weeks before measurement of the
lipid profile. Insulin and oral hypoglycemic agents were
maintained in diabetic patients. Plasma was isolated in all
study subjects, after a 12-hour fast, in EDTA-containing
tubes. Lipids and lipoproteins were measured using stand-
ardized techniques and the LDL-cholesterol was calcu-
lated according to the Friedewald formula, unless
triglyceride levels were > 4.5 mmol/L [12,13].
DNA analysis
DNA was isolated from the buffy coat obtained after cen-
trifugation of whole blood. Two previously reported com-
mon polymorphisms of the SMPD1 gene in Niemann-
Pick disease type A and B [14,15] were examined. The
G→A substitution at position c.1522 located in exon 6 of
the SMPD1 gene, predicting a substitution of arginine (R)
for a glycine (G) at residue 508 (G508R) (rs1050239) was
detected by polymerase chain reaction followed by diges-
tion with the restriction enzyme MspI  (New England
Biolabs, MA, USA). The hexanucleotide repeat polymor-
phism at the start position c.103 (genomic position:
6368507) [10] was located in exon 1 of the SMPD1 gene
and detected using the sense primer 5'-GTCAGCCGACTA-
CAGAGAAG-3' and the antisense primer 5'-GGCATCTA-
CAATCCATCACT-3'. The antisense primer was
radiolabeled at the 5' end with T4 polynucleotide kinase
and [γ-32P] ATP (PerkinElmer, MA, USA) by standard pro-
cedures. Polymerase chain reaction products were
resolved on a 6% polyacrylamide denaturating gel.
Data analysis
The data was analyzed by examining allele frequencies in
subjects with low HDL-cholesterol versus controls. The
DeFinetti program [16] was employed to test the devia-
tion from Hardy-Weinberg equilibrium and also to com-
pare the frequency of the SNPs between cases and
controls. For the G1522A SNP, HDL-cholesterol levels
were compared between homozygotes of the commonBMC Medical Genetics 2007, 8:79 http://www.biomedcentral.com/1471-2350/8/79
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allele and both heterozygotes and homozygotes for the
rare allele pooled together. Deviation from Hardy-Wein-
berg equilibrium for the hexanucleotide repeat polymor-
phism was tested by PEDSTATS version 0.6.5. The CLUMP
program version 2.3 was used to assess the significance of
the same marker between cases and controls, by using
1000 simulations in a Monte Carlo approach [17].
Haplotype frequencies (containing both polymorphisms)
were estimated for cases and controls, using PHASE ver-
sion 2.02 [18].
Power calculations using the Genetic Power Calculator
[19] demonstrated that we would have > 80% power with
our given sample size (controls = 230, cases = 118) to
detect a SNP that accounts for 0.02 or more of the variance
in HDL-cholesterol. This assumes that we are directly test-
ing a causitive variant with an allele frequency of 23%
with a type I error rate α = 0.05.
Statistical analyses were performed with the SAS package
version 8 (SAS Institute Inc., NC, USA) and SigmaStat ver-
sion 2.0 (Jandel Corporation, San Rafael, CA, USA). A χ2
analysis (GraphPad InStat, CA, USA) was performed with
respect to allele frequencies in each of the HDL-cholesterol
groups. Age, body mass index (BMI), and all lipid param-
eters in both groups were treated as continuous variables.
Comparisons were made through generalized linear
model procedures (Proc GLM) followed by Duncan's post
hoc test. All p-values < 0.05 were considered significant.
Results
We analyzed a total of 348 subjects from a pool of control
subjects and patients with premature CAD. The selection
criterion was an HDL-cholesterol < 5th percentile for cases
(n = 118), and an HDL-cholesterol > 25th percentile for
controls (n = 230). Mean ages were 50 ± 10 and 50 ± 9
years for control and case groups, respectively. Additional
demographic and biochemical characteristics are shown
in Table 1. Subjects with a low HDL-cholesterol had a
higher BMI, were more likely to have type II diabetes,
hypertension, CAD and a family history of CAD. These
correlates of low HDL-cholesterol have been previously
well established [20]. The low HDL-cholesterol group had
an HDL-cholesterol of 0.67 ± 0.13 mmol/L and the con-
trol group had a mean HDL-cholesterol of 1.35 ± 0.33 (p
< 0.001). Plasma triglyceride levels were higher in the low
HDL-cholesterol group than in the controls (3.95 ± 3.35
mmol/L vs. 1.63 ± 0.89 mmol/L, p < 0.001).
We examined two polymorphisms at the SMPD1  gene
locus: G1522A (G508R) and a hexanucleotide repeat
sequence CTGG (TC)(GT). From our 348 subjects ana-
lyzed, 230 controls and 117 cases were successfully geno-
typed. The prevalence of the G508R variant in cases and
controls is shown in Table 2. The presence of the G allele
was seen in 75.2% of controls and 78.6% of subjects with
low HDL-cholesterol (OR = 0.82; p = 0.317). The G allele
has been reported at a frequency of 0.85 in an European
population [21]. We also separately analyzed the associa-
tion of this variant between patients with and without
CAD and no significant difference was confirmed (p  =
0.06, data not shown). Genotype frequencies for the GG,
GA and AA classes did not differ between subjects with
low HDL-cholesterol and controls (Table 2). We exam-
ined the association of age, gender, BMI, diabetes melli-
tus, hypertension, plasma triglycerides, CAD, familial
history of CAD, total plasma cholesterol, plasma LDL-
cholesterol, between subjects with the GG genotype and
subjects with either the AG or AA genotypes in cases and
controls (Table 3). We found significant associations
between the genotypic classes with familial history of
CAD (p = 0.0003), total cholesterol (p = 0.03) and LDL-
cholesterol (p = 0.02) in controls. In addition, we found
significant associations between the genotypic classes
with total cholesterol (p  = 0.009) in the low HDL-
Table 1: Baseline characteristics of low HDL-C and control subjects
Control subjects (n = 230) Low HDL-C subjects (n = 118) t test p*
Age (y) 50 ± 9 50 ± 10 0.93
Gender (M/F) 150/80 85/33 0.20
BMI (kg/m2) 26.3 ± 4.5 28.1 ± 4.9 0.001
DM (%) 10.4 21.2 0.01
HTN (%) 20.4 45.8 <0.001
CAD (%) 49.8 72.3 <0.001
FH of CAD (%) 61.3 72.6 0.04
TG (mmol/L) 1.63 ± 0.89 3.95 ± 3.35 <0.001
T Chol (mmol/L) 5.73 ± 1.41 5.98 ± 2.20 0.26
HDL-C (mmol/L) 1.35 ± 0.33 0.67 ± 0.13 <0.001
LDL-C (mmol/L) 3.70 ± 1.33 3.50 ± 1.61 0.27
BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T 
Chol, total plasma  cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low-density cholesterol.
* significant p-value bolded.BMC Medical Genetics 2007, 8:79 http://www.biomedcentral.com/1471-2350/8/79
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cholesterol subjects. We did not find any significant differ-
ence in the prevalence of the GG or AG + AA genotypes
with the presence of diabetes. The analysis was also car-
ried out separately between each genotypic class (GG, AG
and AA), and the results were similar as those presented in
Table 3.
The second polymorphism consisted of a unique hexanu-
cleotide sequence CTGG(TC)(GT) located within the sig-
nal peptide region of the acid sphingomyelinase
(corresponding to the hydrophobic sequence LVLALALA-
LALA). The genotype distribution of the hexamer poly-
morphism was examined and the most frequent allele was
the 6 and 7 repeats (respectively 46% and 47% of the con-
trol group) (Table 4). We identified 9 genotypes in our
study population with the most prevalent being 6/7, 7/7
and 6/6. There was no significant difference in the geno-
type or allele frequencies between low HDL-cholesterol
subjects and controls. We used the CLUMP program to
confirm these results with a p-value of 0.6 after a 1000-
simulation analysis. We examined the most frequent gen-
otypes with respect to age, gender, BMI, diabetes mellitus,
CAD, family history of CAD, triglycerides, total choles-
terol and LDL-cholesterol levels and we found significant
differences between the subgroups of subjects with 6/6, 6/
7, 7/7 for hypertension (p = 0.04) and triglycerides (p =
0.005) in low HDL-cholesterol subjects only (Table 5).
We used the PHASE program to reconstruct haplotypes in
cases and controls. Substantial linkage disequilibrium was
observed as the A allele of G1522A was seen almost exclu-
sively with the hexanucleatide repeat of "6" (Table 6).
Overall haplotype frequencies between cases and controls
were not significantly different (p = 0.5) (Table 6).
Discussion
The present report suggests that common genetic variabil-
ity at the SMPD1 gene locus does not contribute signifi-
cantly to HDL-cholesterol levels in a French Canadian
population. Rare mutations at the SMPD1 gene can cause
Table 2: Genotype distribution and allele frequency of the G1522A variant in the SMPD1 gene in control and low HDL-cholesterol 
subjects.
Genotype or allele Control subjects (n) Low HDL-cholesterol subjects 
(n)
χ2, two-sided p-value and O.R.
GG 56.1% (129) 64.1% (75) 0.152†
AG 38.3% (88) 29.1% (34) 0.72 (0.45–1.13)‡
AA 5.6% (13) 6.8% (8)
G 75.2% 78.6% 0.317
A 24.8% 21.4% 0.82 (0.57–1.20)‡
O.R., odd ratio
† AG and AA genotypes where pooled for statistical analysis
‡ 95% confidence interval for O.R.
Table 3: Comparison of biochemical data of the low HDL-C and control subjects between different groups of G1522A genotypes.
Control subjects t test p * Low HDL-C subjects t test p *
GG AG + AA GG AG + AA
n 129 101 75 42
Age (y) 50 ± 10 50 ± 8 0.5 49 ± 9 51 ± 11 0.4
Gender (M/F) 81/48 69/32 0.3 52/23 32/10 0.4
BMI (kg/m2) 26.4 ± 4.6 26.3 ± 4.4 0.9 28.3 ± 5.2 27.7 ± 4.5 0.5
DM (%) 10.5 10.9 0.9 20.3 19.0 0.9
HTN (%) 19.3 22.8 0.5 51.3 33.3 0.06
CAD (%) 45.9 56.0 0.1 75.4 65.8 0.3
FH of CAD (%) 51.7 75.8 0.0003 75.0 67.5 0.4
TG (mmol/L) 1.60 ± 0.89 1.70 ± 0.89 0.4 4.34 ± 3.89 3.19 ± 1.90 0.07
T Chol (mmol/L) 5.55 ± 1.19 5.96 ± 1.62 0.03 6.33 ± 2.39 5.25 ± 1.56 0.009
HDL-C (mmol/L) 1.34 ± 0.31 1.33 ± 0.33 0.8 0.67 ± 0.13 0.67 ± 0.13 0.9
LDL-C (mmol/L) 3.51 ± 1.10 3.93 ± 1.54 0.02 3.71 ± 1.74 3.17 ± 1.34 0.09
BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T 
Chol, total plasma cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low-density cholesterol.
* significant p-value bolded.BMC Medical Genetics 2007, 8:79 http://www.biomedcentral.com/1471-2350/8/79
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Niemann-Pick disease type A or B, which can differ in
degrees of neurological impairment. Mutations for both
types A and B are distributed throughout the SMPD1 gene
and the structure-function relationship between mutations
and disease states is not fully understood. We and others
have previously reported that patients with Niemann-Pick
disease type A/B have low plasma levels of HDL-choles-
terol [7,8,22]. More recently, we have shown that cellular
cholesterol processing is abnormal in fibroblasts with
SMPD1  mutations [9]. Despite an abnormal lysosomal
transport of cholesterol and sphingomyelin, cellular cho-
lesterol efflux onto apolipoprotein A-I does not appear to
be the rate-limiting step in generating nascent HDL parti-
cles. Instead, our data suggests that abnormal composition
of nascent HDL particles leads to abnormal LCAT activity
and decreased cholesterol esterification when the protein
product of the SMPD1  gene, acid sphingomyelinase, is
defective [9]. It has been previously reported that reconsti-
tuted HDL particles using proteoliposomes with an
increasing ratio of sphingomyelin to phosphatidylcholine
Table 4: Genotype distribution and allele frequency of the hexanucleotide repeat polymorphism in the SMPD1 gene in low HDL-C and 
control subjects
Genotype or allele Control subjects (%) Low HDL-C subjects (%) p
5/5 0.4 0 0.527
5/6 6.3 2.6
5/7 5.4 7.0
6/6 20.3 25.5
6/7 45.6 37.7
7/7 20.3 26.3
7/8 0.4 0
7/9 0.9 0.9
7/10 0.4 0
5 6.3 4.8 0.619
6 46.2 45.6
7 46.6 49.1
8 0.2 0
9 0.5 0.5
10 0.2 0
Table 5: Comparison of biochemical data of the low HDL-C and control subjects between the most prevalent genotypes of the 
hexanucleotide repeat polymorphism in the SMPD1 gene.
Control subjects (n = 230) t test p Low HDL-C subjects (n = 118) t test p*
6/6 6/7 7/7 6/6 6/7 7/7
n 45 101 45 29 43 30
Age (y) 50 ± 8 50 ± 9 49 ± 9 0.79 48 ± 10 51 ± 10 49 ± 10 0.51
Gender (M/F) 30/15 68/33 29/16 0.94 22/7 29/14 20/10 0.69
BMI (kg/m2) 26.1 ± 5.1 26.4 ± 4.0 26.0 ± 4.1 0.86 27.9 ± 4.2 27.8 ± 5.1 29.2 ± 5.6 0.45
D M  ( % ) 1 5 . 05 5 . 03 0 . 00 . 5 71 9 . 04 2 . 93 8 . 10 . 4 7
HTN (%) 23.1 61.5 15.4 0.35 22.2 35.6 42.2† 0.04
C A D  ( % )2 6 . 15 1 . 12 2 . 80 . 7 72 3 . 94 5 . 13 1 . 00 . 1 6
FH of CAD 
(%)
28.3 53.3 18.3 0.05 23.6 43.1 33.3 0.15
TG (mmol/L) 1.60 ± 0.68 1.56 ± 0.85 1.68 ± 0.88 0.71 2.73 ± 1.38 4.94 ± 3.65† 3.57 ± 2.58 0.005
T Chol 
(mmol/L)
6.09 ± 1.45 5.61 ± 1.52 5.82 ± 1.32 0.19 5.56 ± 2.21 6.12 ± 1.77 6.03 ± 2.06 0.48
HDL-C 
(mmol/L)
1.36 ± 0.34 1.33 ± 0.31 1.31 ± 0.28 0.80 0.66 ± 0.11 0.67 ± 0.13 0.69 ± 0.10 0.55
LDL-C 
(mmol/L)
3.96 ± 1.37 3.60 ± 1.34 3.79 ± 1.39 0.32 3.60 ± 2.08 3.38 ± 1.34 3.68 ± 1.62 0.74
BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T 
Chol, plasma cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low density lipoprotein cholesterol.
†significantly different from genotype 6/6.
* significant p value bolded.BMC Medical Genetics 2007, 8:79 http://www.biomedcentral.com/1471-2350/8/79
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inhibits LCAT activity and cholesteryl ester formation [23-
25]. This leads to an inability of HDL particles to mature
into spherical HDL3 particles. In turn, current evidence
points to an increased catabolism of these nascent, choles-
teryl ester-poor HDL particles by the kidney [26].
In a previous report, we have shown that rare mutations of
the SMPD1 gene leads to reduced activity of acid sphingo-
myelinase and is associated with a low HDL-cholesterol.
In addition, the mutations segregate within families with
a gene dosage effect. This gene-dosage effect was shown in
HDL-cholesterol levels in homozygotes and compound
heterozygotes [8]. Here, we have found that the prevalence
of the G1522A substitution (G508R) was not significantly
different in subjects with a low HDL-cholesterol, com-
pared with controls. We used the PolyPhen program [27]
to determine the predicted impact of individual variants
on SMPD1 function and this variant was predicted to be
benign.
Moreover, the presence of the 6 and 7 hexanucleotide
repeats as well as the 10 different haplotypes in cases and
controls were not significantly different. In a previous
report, the 5 separate alleles, corresponding to 9, 7, 6, 5
and 4 hexanucleotide repeats were unrelated to Niemann-
Pick disease [15]. Corresponding allele frequencies of
0.5%, 12.4%, 50.4%, 34.9% and 1.8% were found in that
study, generating 9 different genotypes [15].
Some significant associations were found between
SMPD1 genotypic classes and characteristics of the cases
and control subjects. For example, in the control group,
carriers of the 1522A had a significant increase in family
history of CAD, plasma LDL-cholesterol and total choles-
terol levels. However, the 1522A allele was associated
with lower total plasma cholesterol concentrations in the
cases. Given the lack of consistency of these results
between the control and low HDL-cholesterol groups, and
the relative statistical weakness of these associations (not
significant or only marginally significant when Bonferroni
corrections are applied for multiple testing), the clinical
relevance of these findings is uncertain and are probably
the result of multiple statistical tests.
This study is limited by the relatively small number of sub-
jects (n = 348). However, we did have greater than 80%
power to detect a genetic variant that accounts for as little as
2% of the variance of HDL-cholesterol. In addition, we used
arbitrary cut-points of an HDL-cholesterol < 5th percentile
and > 25th percentile for cases and controls, respectively.
These data should still be confirmed in a large-scale study.
Conclusion
Our data suggest that while rare mutations at the SMPD1
locus can cause Niemann-Pick disease types A and B and the
concomitant low HDL-cholesterol, the two common coding
non-synonymous variants that we examined at this locus do
not appear to influence HDL-cholesterol levels to any great
extent. Forty-five mutations in SMPD1 gene causing differ-
ent forms of Niemann-Pick disease type A and B have been
described [28]. Since the incidence of Niemann-Pick disease
type B is difficult to estimate due to the lack of enzyme test-
ing in clinic, variability in symptoms and the lack of knowl-
edge of Niemann-Pick disease type B by treating physicians,
many patients remain undiagnosed [28]. It remains to be
determined if variations in the SMPD1 gene, affecting the
activity of acid sphingomyelinase, might contribute to the
modulation of HDL-cholesterol levels in the general popula-
tion. This study did not examine rare mutations and thus
carrier status for Niemann-Pick disease type B was not ruled
out in either group. However, Niemann-Pick disease type B
should not be common enough to influence our findings.
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